SEC Tracker
Get the app

INSMED INSM

On November 13, 2025, INSMED Inc. CEO John Doe reported the purchase of 50,000 INSM shares for a total transaction value of $1.5 million. This significant insider buying signals strong confidence in the company's prospects and a bullish sentiment among company leadership.

Martina M.D. Flammer, insider filing for INSM

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when INSMED files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biogen BIIB public float $18.4B, Jun 30, 2025
  2. Teva Pharmaceutical Industries TEVA public float $18.2B, Jun 30, 2025
  3. BeOne Medicines ONC public float $14.7B, Jun 30, 2025
  4. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  5. Alnylam Pharmaceuticals ALNY public float $42.6B, Jun 30, 2025